Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, February 1, 2023
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
Carter Gould Maintained (AMGN) at Sell with Decreased Target to $230 on, Feb 1st, 2023
Carter Gould of Barclays, Maintained "Amgen Inc." (AMGN) at Sell with Decreased Target from $240 to $230 on, Feb 1st, 2023.
Carter has made no other calls on AMGN in the last 4 months.
There are 3 other peers that have a rating on AMGN. Out of the 3 peers that are also analyzing AMGN, 1 agrees with Carter's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- David Risinger of "SVB Leerink" Maintained at Hold with Increased Target to $282 on, Thursday, December 22nd, 2022
These are the ratings of the 2 analyists that currently disagree with Carter
- Christopher Raymond of "Piper Sandler" Maintained at Buy with Decreased Target to $293 on, Thursday, January 19th, 2023
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $282 on, Friday, November 4th, 2022
